{"filing":{"accession_number":"0001493152-26-028610","cik":"0001053369","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226028610/form8-k.htm"},"events":[{"id":10885,"run_id":9549,"accession_number":"0001493152-26-028610","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Elite Pharmaceuticals disclosed positive results from a pivotal bioequivalence study for a generic anticonvulsant product, demonstrating bioequivalence to the branded product and indicating the company's intent to file an Abbreviated New Drug Application (ANDA) with the FDA. While this represents material progress toward a regulatory milestone that could affect future revenue and competitive position, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, impairment, or other defined event types). The disclosure is material to investors as it signals advancement in the company's pipeline and regulatory pathway.","company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":7313,"accession_number":"0001493152-26-028610","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Elite Pharmaceuticals disclosed positive results from a pivotal bioequivalence study for a generic anticonvulsant product, demonstrating bioequivalence to the branded product and indicating the company's intent to file an Abbreviated New Drug Application (ANDA) with the FDA. While this represents material progress toward a regulatory milestone that could affect future revenue and competitive position, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, impairment, or other defined event types). The disclosure is material to investors as it signals advancement in the company's pipeline and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T11:03:06.653386+00:00","company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","filing_date":"2026-06-15"}]}